Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Kesimpta®
( ofatumumab )Neuroscience -
Jakavi®
( ruxolitinib )Oncology -
Jadenu® /Jadenu® Sprinkle
( deferasirox )Oncology -
Ilevro®/Nevanac®
( nepafenac )Ophthalmology -
Ilaris®
( canakinumab )Immunology and Dermatology -
Gleevec®/Glivec®
( imatinib mesylate )Oncology -
Gilenya®
( fingolimod )Neuroscience -
Galvus®
( vildagliptin )Cardiovascular, Renal and Metabolism -
Femara®
( letrozole )Oncology